MedTrace Logo

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

NCT03763253 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 433

Last updated 2025-02-07

No results posted yet for this study

Summary

Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment

Conditions

Interventions

COMBINATION_PRODUCT

Standard of Care

Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).

PROCEDURE

Minimally Invasive Ablative Therapy (MIAT)

MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate. Metastatic Directed Therapy available for use.

PROCEDURE

Radical Therapy (Prostatectomy or Radiotherapy)

Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose). Metastatic Directed Therapy available for use.

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Hashim U Ahmed, FRCS Urol · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2026-08-31
Completion
2027-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03763253 on ClinicalTrials.gov